Cameco Q4 Earnings Rise, Full-Year Profit Jumps

Cameco reported markedly stronger results for Q4 and full-year 2025, with Q4 revenue rising to $1,201 million (from $1,183m) and net earnings increasing to $199 million ($0.46/share) versus $135 million ($0.31) a year earlier; adjusted Q4 net earnings were $217 million and adjusted EBITDA was $591 million. For full-year 2025, revenue climbed to $3,482 million from $3,136 million, net earnings attributable to equity holders surged to $590 million ($1.35/share) from $172 million ($0.39), adjusted net earnings reached $627 million and adjusted EBITDA was $1,929 million. The results underscore strengthening fundamentals for the uranium producer and may influence commodity-linked positioning, while the stock was trading at $112.97, down $3.42 (2.94%) on the NYSE.

Analysis

Market structure: Cameco’s beat (2025 adj EBITDA $1,929m, +26% YoY; adj EPS $1.44) signals stronger pricing / contracting in the uranium cycle — direct winners are large, low-cost producers (CCJ), utilities with long-term contracts, and services/enrichment providers; losers are small marginal miners and spot-only traders who face margin pressure. The stock’s ~3% intraday dip to $112.97 looks like profit-taking, not a fundamental reversal; expectation of tighter forward supply should sustain pricing power and allow CCJ to re-rate versus smaller peers.

Risk assessment: Key tail risks include regulatory/political actions (export controls, mine suspensions), operational failures (Cigar Lake-style outages), and a sudden release of secondary/sovereign inventories that could push spot prices down >20%. Immediate (days) risk is volatility around guidance updates; short-term (weeks–months) depends on contract announcements; long-term (years) hinges on new reactor builds and sustained contracting. Hidden dependency: Cameco’s earnings mix between spot sales and fixed-term contracts — a shift back to spot exposure would quickly compress margins.

Trade implications: Favor sizeable but disciplined exposure to CCJ: core long equity plus limited-duration options to lever upside while capping drawdown. Consider pair trades long CCJ vs short broad uranium exposure (URA) to capture company execution over commodity moves. Cross-asset: higher uranium prices could tighten credit spreads for producers and lift CAD vs USD; implied vols likely compress after positive prints, favoring debit spreads now.

Contrarian angles: Consensus may underprice binary downside — CCJ trades at ~79x 2025 adj EPS (112.97/1.44) implying high execution expectations; a 15–25% collapse in spot or a production cut would re-rate shares severely. Historical parallel: the 2007 uranium spike shows rapid reversals when secondary supply re-enters. The current sell-off could be an opportunity only if you cap downside and explicitly hedge commodity risk.

Key Decisions for Investors

• Initiate a 2–3% portfolio position long CCJ at ≤ $115 with a 12% stop-loss (~$101) and a 12-month price target of $140 (≈+24%); raise to 4–5% only after two consecutive quarters of sustained EBITDA growth or material long-term contracting news.
• Establish a defined‑risk options sleeve: buy a 9‑12 month call spread (buy Sep/Dec 2026 $115 call, sell $150 call) sized to equal 1% portfolio notional to capture upside while limiting capital at risk; roll or convert to shares on positive catalyst (major LT contract).
• Implement a relative‑value trade: long CCJ (2% weight) vs short URA (0.6 ratio, ~1.2% portfolio) to isolate company-specific upside vs the commodity basket; unwind if CCJ underperforms URA by >15% over a 30‑day rolling window or if uranium spot falls >20% within 60 days.
• Set hard risk triggers to act within 90 days: reduce exposure by 50% if (a) Cameco’s next quarterly guidance cuts adj EBITDA >15% YoY or (b) major Kazakhstan/Russia supply announcement increases projected 12‑month volumes by >10%; increase exposure if company announces new multi‑year contracts covering >20% of 2027 forecasted production.